Good morning. My name is Julianne and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation's Fourth Quarter Investor Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] I would now like to turn the conference over to Glenn David, Chief Financial Officer. Please go ahead.

Thank you, Julianne. Good day and welcome to the Phibro Animal Health Corporation Earnings Call for our Fiscal Fourth Quarter and Full Year ending June 30, 2024. My name is Glenn David and I'm the Chief Financial Officer of Phibro Animal Health Corporation. I'm joined on today's call by Jack Bendheim, Phibro's Chairman, President, and Chief Executive Officer; Daniel Bendheim, Director and Executive Vice President of Corporate Strategy; and Larry Miller, Chief Operating Officer. Today, we will cover financial performance for our fourth quarter and full year 2024 and provide financial guidance for our fiscal year ending June 30, 2025. At the conclusion of our remarks, we will open the lines for your questions. I would like to remind you that we are providing a simultaneous webcast of this call on our website, pahc.com. Also on the Investors section of our website, you will find copies of the earnings press release and annual Form 10-K, as well as the transcript and slides discussed and presented on this call. Our remarks today will include forward-looking statements and actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements section in our earnings press release. Our remarks include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or US GAAP. I refer you to the non-GAAP Financial Information section in our earnings press release for a discussion of these measures. Reconciliations of these no-GAAP financial measures to the most directly comparable US GAAP measures are included in the financial tables that accompany the earnings press release. We present our results on a GAAP basis and on an adjusted basis. Our adjusted results exclude acquisition-related items, unusual, non-operational, or non-recurring items, including stock-based compensation, other income expense as separately reported in the consolidated statement of operations, including foreign currency losses and gains and income taxes related to pretax income adjustments and unusual or non-recurring income tax items. Now let me introduce our Chairman, President, and Chief Executive Officer, Jack Bendheim to share his opening remarks.

Thank you, Glenn, and thank you to everyone joining us this morning. We had a strong finish to the year with our Animal Health business growing sales at 8% in the quarter, led by vaccine growth of 14% and MFA and Other growth of 12%. In the quarter, our Mineral Nutrition segment grew at 6% and while our performance products segment showed a slight decline, both mineral nutrition and performance products had their best quarter of the year, building on the improvements we began to see in the third quarter. We remain very excited about the acquisition of the Zoetis MFA business, we're moving closer to a closing on the deal. Our team is working very hard together with Zoetis to ensure a transition that is as seamless as possible so that the customers are unaffected by the handoff. We expect the transaction to close in the fourth quarter of this calendar year. As Glenn will further detail, we are also providing guidance for our fiscal year 2025, which shows mid-single-digit growth in revenue and a leveraged P&L on a standalone basis. We anticipate the favorable momentum we saw this past quarter will continue in our new fiscal year. On top of this, our adjusted EBITDA and adjusted net income growth are benefiting from an income growth initiative that we have internally called Phibro Forward. This initiative is unlocking additional growth drivers in our business across both revenue and cost-efficiency initiatives. Our guidance also includes one-time costs-related to this initiative that are primarily external consulting fees. We expect even greater benefits from this initiative in our fiscal years 2026 and 2027 results. The guidance provided does not include the pending Zoetis acquisition. Additional guidance on Zoetis will be provided post the deal closing. I look forward to hearing your questions following Glenn's reviews of our financials. Thank you.

Thanks, Jack. And starting with our Q4 performance on Slide 4, consolidated net sales for the quarter ended June 30, 2024, were $273.2 million, reflecting an increase of $18.1 million, or a 7% increase over the same quarter one year ago. The Animal Health segment grew 8%, while Mineral Nutrition grew at 6%, and the Performance Product segment declined by 1%. GAAP net income and diluted EPS decreased significantly, driven by foreign currency losses in the quarter due to the weakening of the Brazilian real and increased SG&A due to higher employee-related costs, partially offset by favorable gross profit as a result of higher product demand in the Animal Health segment. After making our standard adjustments to GAAP results, including acquisition-related items, foreign currency losses, and certain one-off items, fourth quarter adjusted EBITDA increased $1.1 million, or 3% versus the prior year. Adjusted net income and adjusted diluted EPS, both increased 10%. Increased gross profit driven by sales growth was partially offset by higher adjusted SG&A and higher adjusted interest expense, with a benefit from a reduced adjusted provision for income taxes. Moving to the full year. Consolidated net sales for the year ended June 30, 2024, were $1,017 million, reflecting an increase of $39.8 million, or a 4% increase over the prior year. The Animal Health segment grew 7%, while Mineral Nutrition was flat and the performance products segment declined by 10%. GAAP net income and diluted EPS decreased significantly, driven by foreign currency losses in the Argentine peso and Brazilian real, increased SG&A due to pension settlement costs, and higher employee-related costs and higher interest expense, partially offset by favorable gross profit as a result of higher product demand in the Animal Health segment. Income tax expense decreased by $13 million. After making our standard adjustments to GAAP…

[Operator Instructions] Our first question comes from Michael Ryskin from Bank of America. Please go ahead, your line is open.

Great. Thanks for taking the questions. First, Glenn, you just went through right there in terms of the components of the guide for fiscal year '24, but I was wondering if you could provide a little bit more color on MFAs, Nutritional Specialties, Vaccines, just what are the various drivers of each? What are the puts and takes that sum up to that overall 5% revenue guide?

Sure. So when you look at the performance for next year, Mike, for fiscal year 2025, we're excited about continued growth in Animal Health and also improvement that we expect to see in both Mineral Nutrition and Performance Products, which struggled a bit in the first half of fiscal year 2024 that saw a recovery in fiscal year 2025. Specifically to your question on Animal Health, again, we see that continuing to perform well in 2025, still growth in our MFA business, a recovery in our Nutritional Specialty, and still growth in our Vaccines, but probably a little less than we saw in 2024, as we had the introduction in Brazil, particularly [IV bar products] (ph).

Okay. Okay. And then, another question on Phibro Forward, you flagged this a couple times in the PR, in the prepared remarks, just a little bit more color on the magnitude of the cost efficiencies, and any -- what are the growth drivers and particular focus on -- how should we think about the timing of this being rolled out?

Yeah. So I'll start a little bit and then I'll ask Daniel to comment as well. So we're in the early stages of this initiative right now. We do expect benefits in fiscal year 2025, but we expect those to expand as we move into fiscal year 2026 and 2027. And the initiatives go across a number of areas, as I mentioned, both revenue growth drivers, as well as cost savings initiatives that we're looking at in areas such as procurement and other areas as well. We do expect that, in '26 and '27, this initiative will allow us to provide EBITDA and adjusted net income growth beyond our historical levels, and as we get further into the process, we'll provide more guidance for those future years. And, Daniel, I don't know if you want to add.

Thanks. Not much to add. Focused on deliverable performance, focused on both recurring EBITDA as well as cash flow, so we do see some positive -- we do anticipate some positives there as well this year, as well as in the future years. And as Glenn said, there's literally dozens of initiatives that -- some of them very small, some of them are larger, that sum up to kind of where we hope to be in a couple of years.

Okay. And then one last one, if I could squeeze in on the Zoetis MFA deal? Just around the deal itself, are there any regulatory steps or anti-trust requirements we should be aware of from an HSR perspective? Are there any geographies where you need regulatory approval? Just walk us through that part of it. Thanks.

Sure. So there were two markets where we required regulatory approval, Mike. One in the US -- one being the US, obviously, and the one outside of the US. We've already cleared all the requirements for the US, so we're very excited about that. There's one additional market. We're very confident in the ability to get approval there. It's just more of a timing with their existing processes and that's what drives our expectation that we will close the deal in Q4 calendar year this year.

Great. Thanks so much.

[Operator Instructions] Our next question comes from Navann Ty from BNP Paribas. Please go ahead, your line is open.

Hi, good morning. About the Zoetis deal, can you discuss your integration plans and the integration work you have been doing before the deal closes? And then a question on refinancing, if you have completed all of it, and do you have higher covenant headroom as you anticipated? Thank you.

Sure. In terms of the integration plans, obviously, we've been working diligently as an organization to be prepared to bring the business into Phibro and be effective when we take over the business and make sure that we could effectively support our customers. We are working with third-party consultants to help us to do that, as well we're very confident in our ability to take over the business on day one, and we are building additional resources internally in markets where we may not have the level of presence to support the magnitude of the business that we are acquiring from Zoetis. As we mentioned, we're very excited about what that adds to us in certain areas, in particular, particularly the expansion that provides to us in China, as well as the expansion in the US beef market. Related to the re-financing, we are done with the re-financing. As I mentioned in the prepared remarks, it does also provide for an additional delayed draw loan on the closing of the Zoetis acquisition of $350 million to help us finance that acquisition. So that is pending the deal close.

Thank you.

There are no further questions at this time. I would like to turn the call back over to Glenn David for any closing remarks.

We thank you all for your interest in Phibro Animal Health, and we appreciate the questions and hope everybody has a great day. Thank you.

This concludes today's conference call. You may now disconnect.